EUCTR2008-008713-20-DK进行中（未招募）不适用
EP4 receptor antagonism and PGE2 in a human headache model
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Healthy trial subjects of either gender, 18–55 years of age.
- •Body Mass Index 21–29 kg/m2 [body mass index = body weight (kg) ÷ height (m)]2.
- •Fertile women must use reliable contraception; this does not apply to women who have had hysterectomies or to women 2 years post-menopause or longer. Reliable contraception is either an IUD + condom, birth control pills + condom, surgical sterilisation of the woman, or a depot gestagen.
- •Non-smokers or ex-smokers who have not smoked in the last 6 months (determined by urine cotinine < 500 ng/ml at screening).
- •No clinically significant out of range values in tests of serum biochemistry, hæmatology or urinalysis at screening (see Appendix 1).
- •Negative urinary drugs of abuse screen at screening (see Appendix 1).
- •Negative HIV and hepatitis B and C results
- •Trial subjects must fulfil the inclusion criteria entirely, be willing and able to comply fully with the requirements of the study and be available to take part in the study.
- •Trial subjects must be found to be healthy in a physical examination before the study begins.
- •Trial subjects must sign the informed consent for participation in the study. Subjects will be informed about the nature, procedures, requirements, and restrictions of the trial. They will also be informed about risks, benefits/ compensation, and confidentiality (data protection), as well as about the voluntary nature of participation and whom to contact regarding questions or problems. Each subject willing to participate in the trial must sign and date an informed consent document, a copy of which will be given to the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Tension headache [32] more than once a month on average in the recent years.
- •All other primary forms of headache [32].
- •Painful or inflammatory diseases.
- •Raynaud’s phenomenon.
- •Systemic sclerosis or vasculitis.
- •Gastric ulcers or dyspepsia.
- •Gastrointestinal disease with possible influence on the uptake of medicine.
- •NSAID hypersensitivity.
- •Known allergy to the study drug constituents including lactose (incompatibility)
- •Intake of prescription or over-the-counter medicine within 14 days before the first study day. Daily intake of medicine of any kind except for an oral contraceptive.
- •Intake of any form of medicine later than 4 times the plasma half-life of the relevant substance (on the study day) apart from an oral contraceptive.
- •Vitamins, minerals and other nutritional supplements may be taken upon having notified the investigator of them.
- •Previous history with any relevant abnormal findings for kidney, liver, mental, neurological, respiratory, cardiovascular or gastrointestinal diseases.
- •Abnormal laboratory findings pointing to infectious, endocrinal, or other systemic diseases.
- •Trial subjects must not have abnormal ECG deviations within a period of 14 days before the first dose.
- •Pregnant or lactating women (negative urine HCG pregnancy test at screening)
- •Headache on the study day or within 24 hours before intake of the study medicine or placebo.
- •Trial subjects must not have clinically significant deviations in blood pressure or pulse within 14 days before the first dose.
- •Persons with systolic blood pressure elevation greater than 20 mmHg or pulse increased more than 20 beats per minute on changing from a supine to standing position.
- •Inclusion interview revealing medical history or clinical signs of:
- •ohypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg);
- •ohypotension (systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg).
- •Cardiovascular disease of any kind, including cerebrovascular disease.
- •Anamnestic or clinical signs of mental illness or substance abuse
- •Trial subjects not willing to limit alcohol intake to 2 units per day for 7 days before the first dose and to entirely abstain from alcohol consumption 2 days before the study days until the trial period is finished.
- •Trial subjects not willing to abstain from caffeine intake 2 days before the study and until the end of the study.
- •Incapacity to communicate properly with the investigator (due for example to speech difficulties, insufficient mental development, or reduced cerebral function).
- •Participation in a clinical study of a medicine without regulatory approval or marketing authorisation within 1 month before this trial.
- •Blood donation >500 ml within last 3 months.
- •Trial subjects subject to time changes and/or jet lag due to long distance travel or work in the night hours.
研究者
相似试验
已完成
1 期
EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache ModelHeadache, MigraineNCT00957983Danish Headache Center8
已完成
不适用
Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2HeadacheMigraineNCT00374530Danish Headache Center12
已完成
不适用
Prostaglandin E2 in Migraine Suffers Without Aura."Migraine-like" HeadacheNCT01384812Troels Wienecke12
Unknown
不适用
Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2HeadacheVasodilatationMigraineNCT00510172Glostrup University Hospital, Copenhagen12
终止
1 期
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy VolunteersHeadacheMigraineNCT00291395Danish Headache Center12